Cancers, Vol. 16, Pages 1475: Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review
Cancers, Vol. 16, Pages 1475: Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review
Cancers doi: 10.3390/cancers16081475
Authors:
Marianna Criscuolo
Maria Elena Tosti
Alessandro Broccoli
Marzia Varettoni
Alessio Maria Edoardo Maraglino
Antonella Anastasia
Maria Cantonetti
Livio Trentin
Sofia Kovalchuk
Lorella Orsucci
Marina Deodato
Angelica Spolzino
Stefano Volpetti
Ombretta Annibali
Sergio Storti
Caterina Stelitano
Francesco Marchesi
Sonia Morè
Luana Fianchi
Brunangelo Falini
Alessandro Pulsoni
Enrico Tiacci
Pier Luigi Zinzani
Livio Pagano
Concern has emerged about the prevalence of second cancers among patients with hairy cell leukemia (HCL) treated with purine analogs. We investigated 513 patients with HCL treated with cladribine over the last 30 years at 18 Italian centers and calculated their standardized incidence ratios (SIRs). We identified 24 patients with a second cancer diagnosed at a median time from treatment with cladribine of 59.9 months (range: 9.2–169.7 months). All patients with solid neoplasms presented with a limited-stage disease, except four cases of locally advanced cancer; multiple myeloma patients had a smoldering disease, while lymphoma patients had stage Ie and stage IV diseases. Response to therapy was complete in 19 cases; 1 patient is still receiving treatment for a relapsing bladder disea...
Source: Cancers - Category: Cancer & Oncology Authors: Marianna Criscuolo Maria Elena Tosti Alessandro Broccoli Marzia Varettoni Alessio Maria Edoardo Maraglino Antonella Anastasia Maria Cantonetti Livio Trentin Sofia Kovalchuk Lorella Orsucci Marina Deodato Angelica Spolzino Stefano Volpetti Ombretta Annibal Tags: Article Source Type: research
More News: Bladder Cancer | Broccoli | Cancer | Cancer & Oncology | Hairy Cell Leukemia | Italy Health | Leukemia | Lymphoma | Myeloma | Statistics